MedTrace Logo

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1077

Last updated 2012-08-08

Study results available
· View outcomes & findings →

Summary

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

Conditions

  • Skin/Soft Tissue Infections
  • Methicillin Resistant Staphylococcus Aureus (MRSA)

Interventions

DRUG

linezolid

DRUG

vancomycin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States
  • Argentina
  • Belgium
  • Brazil
  • Chile
  • Colombia
  • Italy
  • Malaysia
  • Mexico
  • Portugal
  • Russia
  • Singapore
  • South Africa
  • Spain
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00087490 on ClinicalTrials.gov